A5032877149- PI3K/AKT/mTOR signaling in cancer
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cleft Lip and Palate Research
- dental development and anomalies
- HER2/EGFR in Cancer Research
- CRISPR and Genetic Engineering
- Genomic variations and chromosomal abnormalities
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- DNA Repair Mechanisms
- Prenatal Screening and Diagnostics
- Craniofacial Disorders and Treatments
Wroclaw Medical University
2017-2022
Lublin Oncology Center
2022
Dolnośląskie Centrum Onkologii
2021
Wroclaw Research Centre EIT+ (Poland)
2020
Breast and ovarian cancers are among the most common malignancies in female population, with approximately 5-10% of cases being hereditary. BRCA1 BRCA2 other homologous recombination genes tested hereditary breast cancer (HBOC) patients. As next-generation sequencing (NGS) has become a standard popular technique, such as for HBOC, it greatly simplified accelerated molecular diagnosis cancer. The study group included 3,458 HBOC patients or their relatives from Lower Silesia (Poland) (a...
Szybka diagnostyka najczęstszych aneuploidii u płodu metodą QF-PCR -analiza 100 przypadkówRapid diagnosis of the most common fetal aneuploidies with method -a study cases ,]DEHOD àDF]PDĔVND 1,2 -XVW\QD *LO $JQLHV]ND 6WHPEDOVND 0DNRZVND -RDQQD .R
Indywidualizacja postępowania medycznego oparta na markerach prognostycznych i predykcyjnych (medycyna personalizowana) pozwala personalizację profilaktyki zoptymalizowanie leczenia poprzez zwiększenie jego skuteczności zminimalizowanie działań niepożądanych. W przypadku raka piersi podstawą doboru terapii pozostaje ocena histopatologiczna immunohistochemiczna z analizą ekspresji receptora dla estrogenów ( estrogen receptor – ER), progesteronu progesterone PgR) oraz nadekspresji ludzkiego...
Personalised treatment which is a dynamically developing branch of medicine, based on individualisation diagnostic and therapeutic procedures. Its aim to optimise by increasing therapy effectiveness, while minimising side effects. It designed both for patients with diagnosed hereditary cancer syndrome, as well those sporadic cancers. In the case colorectal cancer, personalised requires patient selection predictive factors. This involves determination genetic status within epidermal growth...